At this conference we focus on initiatives in academia and industry and the need for collaboration as well as framework conditions needed to put research to use for the benefit of patients and society.
Watch video with pictures of all who were on stage (3 minute and 4 seconds with music).
Programme
08:00–08:30 Registration and breakfast
Place: Area outside Forum auditorium
08:30–10:00 Impact Breakfast: Antimicrobial resistance – a global challenge with urgent need for new solutions
Place: Area outside Forum auditorium
- Welcome to Science Impact 2025
Jens Petter Berg, Vice-Rector for life science and health research, University of Oslo - Antibiotic resistance – how worried should we be?
Kristian Tonby, MD, PhD, associate professor, Institute of Clinical Medicine, UiO and Oslo University Hosptial (OUS) - New therapy against drug-resistant tuberculosis
Tone T?njum, Professor, Institute of Clinical Medicine, UiO and OUS - What does it take to develop a new antibiotic? – from bioprospecting to AI-supported identification
Geir Klinkenberg, research manager, SINTEF - Inventing and developing novel resistance breakers
Bj?rn Klem, COO, AdjuTec Pharma AS - Precision-guided missiles to target harmful bacteria
Jukka Corander, Institute of Basic Medical Sciences, UiO - Developing diagnostic device to detect drug resistant bacteria
Elizaveta Vereshchagina, PhD, senior research scientist, SINTEF - Development of new antibiotics from the perspectives of a large pharmaceutical company
Kristin L?seth, medical director Norway, AstraZeneca
Chairperson: Jens Petter Berg, Vice-Rector for life science and health research, University of Oslo
10:00–10:30 Networking
10:30–12:00 Parallel sessions
Cancer treatment – Oslo a world-leading hub for radiopharmacy
Place: Forum auditorium
- Theranostics – targeted radionuclide therapy
Mona Elisabeth Rootwelt-Revheim, MD, PhD, professor II, head of The Intervention Centre, UiO and OUS - Building competence and infrastructure on radionuclides
Sunniva Siem, professor Department of Physics UiO, and centre director, the Norwegian Nuclear Research Centre - Transforming cancer care through direct alpha therapy
?ystein Soug, CEO, Oncoinvent -
Challenging cancer indications met with challenging technology
Marion Malenge, head of in vivo radiopharmaceutical development, ARTBIO - Development of radionuclides from the perspectives of a large pharmaceutical company
Jenny Karlsson, senior director targeted radiopharmaceuticals, Bayer - Empowering innovation: The Oslo Imaging and Therapy Laboratory’s support for public and private radiopharmaceutical development
Syed Nuruddin, Preclinical research Manager, The Cyclotron Center and, Associate Professor II, Department of Pharmacy, UiO - Development of a novel targeted radionuclide therapeutic for haematological malignancies, Ada Repetto-Llamazares, PhD, CSO, NucliThera
Chairperson: Ole Kristian Hjelstuen, CEO Inven2
Materials science advancing medical research and development
Place: Toppsenteret
- New technology for precision human tissue and modeling of neurodegenerative diseases
Joel Glover, professor, Institute of Basic Medical Sciences, UiO, Kaja Nordengen, MD, Phd, senior physician, OUS and Michal Mielnik, research manager, SINTEF - PharmaChip: Robust, automated, and sustainable chemical analysis of organoids and organ-on-chip systems
Steven Ray Wilson, professor, Department of Chemistry, UiO and Fr?ydis Sved Skottvoll, PhD, research scientist, SINTEF - Towards more flexible, biocompatible and less invasive brain implants
Florian Dapsance, PhD candidate, Department of Physics, UiO - BreathSense – transforming COPD patient care with ground-breaking hand-held breath diagnostics sensor technology
Elizaveta Vereshchagina, PhD, senior research scientist, SINTEF - Intensive care monitoring of glucose, Nicolas Elvemo, CEO, GlucoSet
Chairperson: Charlotte Berrefjord Bergl?ff, Senior Communications Adviser, SINTEF Digital
12:00–13:00 Networking and lunch
Place: Area outside Forum auditorium and Toppsenteret
13:00–14:30 Parallel sessions
Neuroscience – better diagnosis and treatment of Alzheimer's, Parkinson's and multiple sclerosis
Place: Forum auditorium
- Global and national perspectives on a growing challenge – what has been, what is and what will be?
Geir Selb?k, MD, PhD, professor II, Institute of Clinical Medicine, UiO, and research director, The Norwegian National Centre for Ageing and Health - Modeling brain disease using organoids,
Magnar Bj?r?s, PhD, researcher, Institute of Clinical Medicine, UiO and OUS and professor, NTNU - Therapeutic trials and vaccine studies in multiple sclerosis (MS)
Gro Owren Nygaard, MD, PhD, researcher, Institute of Clinical Medicine, UiO and OUS - Ongoing clinical studies on Alzheimer's disease
Anne-Brita Knapskog, MD, PhD, senior consultant, Oslo University Hospital - Challenges and success factors in drug development for neurodegenerative disorders
Susanne Fabre, PhD, senior director translational biomarkers and bioanalysis, BioArctic - Personalized neuro diagnostics with AI
Guro Seternes, CTO, baba - Deep brain stimulation therapy for Parkinson's
J?rn Thomas Waagb?, therapy specialist, Medtronic - New challenges, new opportunities: biomarkers in the fight against Alzheimer’s disease
María José Lagartos Donate, senior scientist, Pre Diagnostics
Chairperson: Hanne Flinstad Harbo, professor, dean, the Faculty of Medicine, UiO
Research in use – how to create impact through social innovation
Place: Toppsenteret
